Heron Therapeutics (HRTX) Total Current Liabilities (2010 - 2026)

Heron Therapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $90.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 2.21% year-over-year to $90.5 million; the trailing twelve-month figure through Mar 2026 stood at $90.5 million (up 2.21% YoY), and the FY2025 full-year result was $96.1 million, up 5.07% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $90.5 million, down from $96.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $258.6 million in Q2 2025, with the low at $75.4 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $97.6 million across 5 years, with a median of $88.6 million in 2025.
• Annual changes were most pronounced in 2023 — Total Current Liabilities slipped 20.8% — and 2025, when it jumped 221.98%.
• Heron Therapeutics' Total Current Liabilities stood at $82.4 million in 2022, then fell by 3.24% to $79.7 million in 2023, then rose by 14.77% to $91.5 million in 2024, then advanced by 5.07% to $96.1 million in 2025, then slipped by 5.81% to $90.5 million in 2026.
• The last three Total Current Liabilities figures came in at $90.5 million (Q1 2026), $96.1 million (Q4 2025), and $89.7 million (Q3 2025), per Business Quant data.